The FDA’s new draft guidance clarifies how drug developers can validate and use non-animal testing methods, reducing regulatory uncertainty and accelerating adoption of human-relevant…
Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence Updated 2026 guidance to be provided upon transaction close RADNOR, Pa., April 22,…